Operating
Stock-Based Comp
Alnylam Pharmaceuticals Stock-Based Comp decreased by 2.1% to $70.15M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.7%, from $56.71M to $70.15M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 20.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $32.08M | $33.37M | $44.58M | $29.29M | $30.47M | $128.12M | $42.77M | $39.95M | $75.80M | $63.94M | $41.99M | $45.35M | $89.29M | $45.80M | $91.65M | $56.71M | $111.68M | $108.21M | $71.63M | $70.15M |
| QoQ Change | — | +4.0% | +33.6% | -34.3% | +4.0% | +320.5% | -66.6% | -6.6% | +89.8% | -15.7% | -34.3% | +8.0% | +96.9% | -48.7% | +100.1% | -38.1% | +96.9% | -3.1% | -33.8% | -2.1% |
| YoY Change | — | — | — | — | -5.0% | +284.0% | -4.1% | +36.4% | +148.8% | -50.1% | -1.8% | +13.5% | +17.8% | -28.4% | +118.2% | +25.1% | +25.1% | +136.2% | -21.8% | +23.7% |
Range$29.29M – $128.12M
CAGR+17.9%
Avg YoY Growth+44.8%
Median YoY Growth+20.7%
Current Streak3 quarters decline
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's stock-based comp?
- Alnylam Pharmaceuticals (ALNY) reported stock-based comp of $70.15M in Q1 2026.
- How has Alnylam Pharmaceuticals's stock-based comp changed year-over-year?
- Alnylam Pharmaceuticals's stock-based comp increased by 23.7% year-over-year, from $56.71M to $70.15M.
- What is the long-term trend for Alnylam Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's stock-based comp has grown at a 20.4% compound annual growth rate (CAGR), from $165.72M to $348.24M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.